OmniSpirant Limited
Changing the paradigm of treatment for cancer and respiratory disease.
Changing the paradigm of treatment for cancer and respiratory disease.
OmniSpirant is an early stage therapeutics company based in Ireland founded in 2016. The company is on a mission to change the paradigm of treatment for cancer and respiratory diseases through its innovative inhaled stem cell exosomes platform technology. OmniSpirant's proprietary technologies, which encompass the synergistic potential of regenerative medicine and gene therapy, have the potential to revolutionize treatment for millions of patients. The company recently secured a €71.43K grant investment on 01 January 2019, with the funding provided by EASME - EU Executive Agency for SMEs. With its focus on the biotechnology industry, OmniSpirant holds promise for transforming the landscape of medical treatments for cancer and respiratory diseases.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | €71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Jan 2019 |
No recent news or press coverage available for OmniSpirant Limited.
We care about your data, and we'd love to use cookies make your experience better.
